Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.82 |
| ▸ | CES1 | P23141 | 2/20 | 0.82 |
| ▸ | TP53 | P04637 | 1/20 | 0.73 |
| ▸ | TSHR | P16473 | 3/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.57 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.57 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | MITF | O75030 | 1/20 | 0.56 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | KMO | O15229 | 1/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | PHGDH | O43175 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15180827 | 1.00 | CES2 (0.82) | CES2CES1TP53TSHRALDH1A1 | |
| SCHEMBL2156825 | 0.90 | CES1 (1.00) | CES2CES1TP53TSHRALDH1A1 | |
| SCHEMBL31374765 | 0.90 | CES1 (1.00) | CES2CES1TP53TSHRALDH1A1 | |
| SCHEMBL31454134 | 0.89 | CES2 (0.89) | CES2CES1TP53TSHRALDH1A1 | |
| SCHEMBL11295400 | 0.89 | CES2 (0.89) | CES2CES1TP53TSHRALDH1A1 | |
| Benzil SCHEMBL27905655 | 0.85 | CES2 (0.81) | CES2CES1TP53TSHRALDH1A1 | |
| SCHEMBL27709081 | 0.85 | TP53 (1.00) | CES2CES1TP53TSHRALDH1A1 | |
| SCHEMBL132618 | 0.85 | TP53 (1.00) | CES2CES1TP53TSHRALDH1A1 | |
| SCHEMBL29490968 | 0.85 | TP53 (1.00) | CES2CES1TP53TSHRALDH1A1 | |
| SCHEMBL6831438 | 0.84 | CES1 (0.86) | CES2CES1TP53TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4323066-A1 | MEK INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2024-02-21 | — | — | EP | disclosed |
| CN-117580835-A | MEK inhibitors and uses thereof | 医肯纳肿瘤学公司 | 2024-02-20 | — | — | CN | disclosed |
| US-20240027902-A1 | CHEMICALLY AMPLIFIED RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2024-01-25 | — | — | US | disclosed |
| US-20230359119-A1 | RESIST COMPOSITION AND PATTERN FORMING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-11-09 | — | — | US | disclosed |
| US-20230305394-A1 | RESIST COMPOSITION AND PATTERN FORMING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-09-28 | — | — | US | disclosed |
| US-20230305393-A1 | RESIST COMPOSITION AND PATTERN FORMING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-09-28 | — | — | US | disclosed |
| WO-2022221866-A1 | MEK INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2022-10-20 | — | — | WO | disclosed |
| CN-106905316-B | Protein kinase inhibitors | 上海复尚慧创医药研究有限公司 | 2021-06-01 | — | — | CN | disclosed |
| EP-2986611-B1 | CERTAIN PROTEIN KINASE INHIBITORS | SHANGHAI FOCHON PHARMACEUTICAL CO LTD (CN) | 2019-02-06 | — | — | EP | disclosed |
| US-10022374-B2 | Certain protein kinase inhibitors | SHANGHAI FOCHON PHARMACEUTICAL CO., LTD. (CN) | 2018-07-17 | — | — | US | disclosed |
| US-20130178505-A1 | Compounds for the Inhibition of Cellular Proliferation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130178505-A1 | Compounds for the Inhibition of Cellular Proliferation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-07-11 | — | — | US | disclosed |
| EP-2585453-A2 | COMPOUNDS FOR THE INHIBITION OF CELLULAR PROLIFERATION | President and Fellows of Harvard College (US) | 2013-05-01 | — | — | EP | disclosed |
| WO-2012006068-A2 | COMPOUNDS FOR THE INHIBITION OF CELLULAR PROLIFERATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012006068-A2 | COMPOUNDS FOR THE INHIBITION OF CELLULAR PROLIFERATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-01-12 | — | — | WO | disclosed |
| US-7442485-B2 | Lithographic process involving on press development | FUJIFILM CORPORATION (JP) | 2008-10-28 | — | — | US | disclosed |
| EP-1484177-B1 | Lithographic process involving on press development | FUJIFILM CORP (JP) | 2007-08-29 | — | — | EP | disclosed |
| US-20050016402-A1 | Lithographic process involving on press development | FUJI PHOTO FILM CO., LTD. | 2005-01-27 | — | — | US | disclosed |
| EP-1484177-A2 | Lithographic process involving on press development | FUJI PHOTO FILM CO., LTD. (JP) | 2004-12-08 | — | — | EP | disclosed |
| US-3969401-A | ANTIINFLAMMATORY, ANALGESIC, ANTIPYRETIC | WILLIAM H. RORER, INC. (US) | 1976-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10022374-B2 | Certain protein kinase inhibitors | PRKACA, PRKACB, PRKDC | CES2 2996/4885CES1 3062/4885TP53 624/4885 |
| US-20130178505-A1 | Compounds for the Inhibition of Cellular Proliferation | MKI67, EIF2AK2, CDK2 | CES2 3167/4885CES1 2856/4885TP53 352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.